Showing 1 - 10 of 97
We have reported our highest ever revenue of £286m, up 8% from £264m* the previous year. The most significant growth came in North America, where revenue was up 24% to £55m, following a continued growth period fed by work from new and existing clients, a series of lateral hires and the opening of a new office in Delaware.
Artificial intelligence in life sciences: regulating AI technologies and the product liability implications
There has been some form of regulation of AI technologies in many life sciences uses in the EU and UK for several years. The EU’s lead on AI regulation began within the medical devices sphere with the introduction of the Medical Device Regulations and In Vitro Diagnostic Regulations (IVDR) (2017/745 and 746) that, belatedly, came into force on 26 May 2021.
In this report, Kennedys experts highlight recent legal and regulatory developments in the product safety and product liability sphere, and provide an overview of the key topics and trends that are likely to impact upon corporates and their insurers in the months ahead.
While artificial intelligence (AI) technologies bring tremendous benefits and opportunities to life sciences businesses, the threats associated with such technologies are wide ranging and complex. This can be exacerbated if companies move too quickly to adopt such sophisticated systems without implementing appropriate securities to protect them.
Kennedys receives top tier rankings in the latest guide to leading law firms and lawyers across the region.
Two years into the pandemic, we consider its impact on the life science sector and how the risk landscape is evolving as the industry builds on the progress it has made.
Artificial intelligence (AI) has transformed the life sciences industry in ways that we could never have imagined. It now impacts each stage of a life science product’s lifecycle — from research and drug discovery to clinical trials, manufacturing, supply chain logistics, marketing, and sales.
On 10 September 2021 the government published a consultation on reforms to data protection law in the UK. Data: A new direction (the Consultation) proposes wholesale change to the UK legal framework, including the UK General Data Protection Regulation (UK GDPR). The changes, if implemented, are wide-ranging and significant and reinforce the government’s aim to capitalise on the UK’s “independent status” and create an ambitious, pro-growth and innovation-friendly data protection regime that maintains its high protection standards.
Recently, there have been considerable developments in respect of the EU’s product safety regulatory regime for pharmaceuticals, reflected in a recent consultation on key EU legislation on pharmacovigilance and a report produced by the European Commission on the efficacy of an EU regulation that controls the sale and safety monitoring of medicines.
We are delighted to have appointed one of the country’s leading data specialists as part of a bold new strategy which will revolutionise the way we does business.